Nanogen officials have responded to an FDA warning letter that criticized the firm for apparently marketing its Molecular Biology Workstation without the requisite FDA approvals by pledging to work with the agency to resolve the situation.

The discussions between Nanogen and the FDA are not likely to affect the company's ongoing plan to release its NanoChip 400 System into the same lab market that the FDA said Nanogen's Molecular Biology Workstation is being marketed to improperly.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.